Daily Management Review

FTSE 100 Demonstrates Poor Performance


04/28/2016


The sinking list of FTSE 100 casts different results on different firms.



FTSE 100 Demonstrates Poor Performance
Among other index, the FTSE 100 recently exhibited poor performances which were at the verge of sinking, while Standard Chartered was counted in with the “top performers” for the investors agreed on its “ongoing turnaround”.
 
Even though the company saw a fifty nine percent profit drop earlier this week, while “commodity prices, volatility in Chinese markets and weak emerging market sentiment” continued to be depressing, the investors were “pleased” to see a drop in “loan impairments”. In a comment the Head of Equity Research at Steve Clayton, Hargreaves Lansdown, said:
 “If the bank can hit the 10% return on equity target, and pay out half of earnings as a dividend, then an attractive yield may one day be possible, given the shares are trading far below book value. However, getting there will be easier said than done”.
 
Moreover, BP also did well in the latter half of the day after losing a “$485m” in the first quarter. As per the firm, the low prices of oil were cause of its bleak performance; although the Chief Executive at BP, Bob Dudley thinks:
"Market fundamentals continue to suggest that the combination of robust demand and weak supply growth will move global oil markets closer into balance by the end of the year”.
 
AstraZeneca faced a lot of “pressure” following its attempt of spreading “a double whammy of positive news”, for prior to the market’s opening, the company announced that “the US Food and Drug Administration had approved its Bevespi Aerosphere inhalation aerosol for treating patients with chronic obstructive pulmonary disease”. Digitallook explains:
“The product - glycopyrrolate and formoterol fumarate - is used for the long-term, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema”.
 
However, later on AstraZeneca informed that Ironwood Pharmaceuticals were buying the U.S. Market Rights for “a newly-approved gout drug - Zurampic, or lesinurad”. The deal struck between both the companies enables Ironwood to “sell both Zurampic to treat high levels of uric acid in the blood of gout patients, and a fixed-dose combination of lesinurad and allopurinol”.
 
References:
http://www.digitallook.com/







Science & Technology

With China Set To Dominate, 1 Billion Could Be Using 5G By 2023

Deutsche Telekom unveils next gen 5G mobile antennas in Europe

Diamonds are now the new gold

Expert Body Says Driving In A Driverless Car In An Inebriated Condition Or On Drugs Should Be Legalized

SEC’s EDGAR database vulnerable to cyber threats

Research Says The Risk Of Severe Turbulence On Planes Will Increase Due To Climate Change

Barclays and CLS Group aim to replace SWIFT with blockchain

Designing Of Cars Being Done With Hologram Goggles At Ford

The Already Surging Cyber Attacks Are Set To Rise Even Further, Says A Study

Chinese to equip smartphones with OLED displays

World Politics

World & Politics

Scholar Says Political Appointees Not As Important As Financial Ones In China For The Economy

An Expected Change In Brussels Could Be Crucial For The Euro Zone

Destroying People Who Wouldn't Help One Of His Bankrupt Businesses Was All Trump Talked About When He Met Him In 1990s: Branson

Russia Is Worried About America’s Unpredictability

No oil contracts with Iraqi Kurdistan: Iraq’s oil ministry

Donald Trump lost $ 600 million during his presidency

Britain puts its weight behind Europe in the battle between Boeing and Bombardier

EU hopes to keep the Iran nuclear deal afloat